One day, Baiyang's new dosage form metformin nida ® officially listed for sale

The listing will launch on-sitetackle the clinical challenges of compliance, Nida®really achieve a one-timeChina is the world's largest number of diabetics, the ninth edition of the Global Diabetes Map (Diabetes Atlas) shows that China currently has more than 116.4 million people with diabetes, most of whom are type 2 diabetes (T2DM)Metformin, as the first choice for the treatment of type 2 diabetes and the drug of all time, is also the first choice of single-drug therapy and combination therapy, with significant effect of reducing sugarhowever, in the actual clinical application process, the traditional dosage form metformin most need to take more than one day, patients miss, forget the phenomenon is common, poor complianceLong-term irregular drug use caused by poor blood sugar control, volatility, and even more serious diabetes complicationsIn addition, the traditional dosage form metformin, because the drug non-constant speed release, will lead to the concentration of blood drugs suddenly high and low, patients are prone to obvious adverse gastrointestinal reactions, serious people will self-reduce drugs, stop drugs, not conducive to disease treatmentProfessor Ji Linon, Director of endocrinology department at Peking University People's Hospital in, said liveProfessor Ji Linon, director of the endocrinology department of Peking University People's Hospital, pointed out that patientcompliance with the patients caused by multiple daily medications and obvious adverse reactions is a possible cause of the limitations of the clinical application of metforminThe ideal metformin preparation should have long-lasting, stable, comfortable sugar control characteristics, simplify the drug treatment program, effectively improve patient compliancethe permeable pump-controlled release agent metformin naydium ® to solve the traditional metformin more than one day to take the cause of leakage, gastrointestinal adverse reactions and other clinical problems, to achieve convenient and stable sugar control, greatly improve drug compliancepermeable pump control release technology to achieve zero-level release, to help long-lasting smooth sugar controlpermeable pump control release technology as a preparation process at the top of the oral preparation pyramid, with high technical barriers, for the preparation process, preparation equipment, quality control and operator requirements are high, at present, only a few Chinese pharmaceutical enterprises can masterBaiyang Pharmaceutical Director, China's drug research and development senior expert Lei Jifeng said, "as a zero defect through the United States FDA certified slow-control release preparation experts, Baiyang Pharmaceutical after ten years of research broke through the technical barriers, master the penetration pump control release preparation technology, and innovative application symetformin, developed a real one-day sugar-lowering new drug Nida ®." "
Nida ® using a unique single-chamber osmosis pump control release technology, the core contains drugs and osmosis agents, outsourcing a layer of semi-penetration membrane, in the core coating film laser double-sided punching, the use of osmosis pressure principle to make the drug active ingredients at a constant amount and rate released in the human body, can eliminate the concentration of blood clots, and thus reduce the occurrence of side effects with its innovative penetration pump control technology advantages and brand strength, Nida ® has been widely recognized in the U.S market, and with its best-selling in the U.S., the original research products have been delisted in the United States After the listing in China, Nida ® will realize sino-US marketing, domestic and foreign production, so that Chinese patients at home can enjoy the international quality of good medicine, rest assured medicine in addition to technical advantages, Nida ® products in the dose specifications, packaging specifications and other aspects have also made innovations, 30 tablets / bottles more portable®; oral sugar-lowering drug market or the bureau, Baiyang is committed to let people use the international good medicine meters net data show that in 2018 the domestic diabetes drug (chemical medicine and traditional Chinese medicine) market exceeded 60 billion yuan In the next 10 years, the diabetes treatment drug market is expected to exceed 100 billion yuan due to the deepening aging of the population, the iterative upgrading of drug varieties and the guidance of health insurance policies In this 100 billion-level potential market, foreign-funded enterprises occupy the leading position, key city public hospitals chemical diabetes drug products sales in the top ten, 9 are foreign-funded pharmaceutical enterprises however, with the continuous promotion of domestic consistency evaluation, as well as the pharmaceutical companies' own research and development level and research and development process, Chinese pharmaceutical companies continue to ascend the international stage, with foreign pharmaceutical companies on the same stage With its innovative infiltration pump control release technology and its significant advantages in clinical application, the® market for oral diabetes drugs is expected to stand out, accelerate the process of replacing imported drugs, and import sugar-lowering drugs as the dominant market pattern or usher in changes in terms of pricing, the price of the new metformin ® a single piece is about 2 times the price of the domestic ordinary slow release tablet products, while in the United States, the permeation pump-controlled release agent form metformin and ordinary release tablet product price ratio of up to 87 times In order to further benefit Chinese patients, Baiyang Medicine slow-disease drug business unit general manager Yang Wei revealed that in the product market ingress marketing process, will actively communicate with the competent health insurance authorities, and strive to enter medical insurance as soon as possible, further reduce the burden of patients' drug costs.